BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

SN BioScience’s Anticancer Candidate SNB-101 Selected for Korea’s 2025 National Drug Development Programme

SN BioScience announced that its anticancer candidate SNB-101 has been selected as a clinical-stage project under the 2025 Korea Drug Development Project, ...

July 17, 2025 | News

Taiwan’s Senhwa Biosciences’ CX-5461 Selected by U.S. National Cancer Institute for Major Oncology Research Programme

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

July 16, 2025 | News

Amarna Therapeutics and NorthX Biologics Advance Nimvec™ AM510 Toward Clinical Trials for Type 1 Diabetes

Fast-Tracking Clinical Readiness: The agreement enables process and analytical development activities required to advance Nimvec™ AM510 for Type 1 ...

July 14, 2025 | News

Elegen and Nutcracker Therapeutics Launch Cell-Free Platform Pilot to Transform RNA-Based Personalised Cancer Therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufactu...

July 14, 2025 | News

Merck & Co. (MSD Outside U.S. and Canada) to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio with Ohtuvayre®

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceu...

July 04, 2025 | News

WuXi AppTec Issues Positive Profit Alert with Over 100% Surge in H1 2025 Net Profit

WuXi AppTec Co., Ltd., a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and m...

July 11, 2025 | News

Earendil Labs Completes First Cohort Dosing in Phase 1 Trial of Novel Anti-TL1A Antibody HXN-1001

Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial for a novel anti-TL1A antibo...

July 11, 2025 | News

BioMed X and Servier Launch Europe’s First XSeed Labs at Paris-Saclay to Accelerate AI-Driven Bispecific Antibody Design

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced the launch of a new initiative with Se...

July 10, 2025 | News

Inocras Partners with Chi Mei Medical Center and Trivator to Advance Precision Oncology in Taiwan

Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, today announced the signing of a Memorandum of Understanding (MOU) with ...

July 09, 2025 | News

Sirtex Secures FDA Approval for SIR-Spheres® Y-90 in Treating Unresectable Hepatocellular Carcinoma

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (F...

July 08, 2025 | News

Celltrion Launches STOBOCLO® and OSENVELT® Biosimilars in the U.S. for Comprehensive Bone Health and Oncology Care

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and X...

July 08, 2025 | News

ImmunityBio Secures First International Approval for ANKTIVA® in the UK for Bladder Cancer Treatment

ANKTIVA, a first-in-class, lymphocyte-stimulating agent, works synergistically with BCG to activate and proliferate natural killer (NK) and T cells, he...

July 08, 2025 | News

InnoCare Pharma Receives IND Approval in China for Novel B7-H3 Targeted ADC ICP-B794

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the approval of the Inves...

July 07, 2025 | News

Akeso Doses First Patient in Phase Ia Trial of AK146D1, the World’s First Bispecific ADC Targeting Trop2 and Nectin4

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a...

July 04, 2025 | News

Stay Connected